Biologics
Precision Medicine. Your Cancer, Your Cure. We design bispecific T-cell engagers that are tailored to your tumor.
Simplicity meets precision. The best of both worlds: Selectively target the patient’s unique cancer fingerprint in the format of an off-the-shelf recombinant biologic.
Uniquely direct with exquisite precision Unlike most immunotherapies, we target the mutated proteins that directly cause cancer.
We engineer therapeutics that selectively find and destroy tumor cells that contain oncogenic driver mutations while sparing healthy cells.
tumor-specific precision targeting Unlocking Solid Tumors
Soluble TCR-like molecules access the intracellular peptidome, enabling tumor-specific precision targeting where current therapies fall short.
Most proteins are intracellular, and few proteins on the cell surface are good drug targets. Therefore, most therapeutic antibodies target the same handful of proteins. Furthermore, these proteins on the surface of tumor cells are also present on healthy cells, leading to on-target off-tumor toxicity. As a result, most cell therapies and many antibody therapies are restricted to liquid tumors which make up only 10% of adult cancers. By using TCR-like molecules to find mutated oncogenic intracellular proteins and kill the cancer cells that contain them, our technology offers solutions to the other 90% of cancers.
Our Program Pipeline
| Program | Indication | Target | Stage |
|---|---|---|---|
| TBB-113 | Multiple solid tumors | CD3 | Discovery |
| TBB-202 | Multiple solid tumors | p53-R175H | Discovery |
| TBB-203 | Pancreatic ductal adenocarcinoma, multiple solid tumors | KRAS-G12D | Discovery |
| TBB-204 | Multiple solid tumors | KRAS-G12V | Discovery |
| TBB-205 | Breast adenocarcinoma, Multiple solid tumors | PI3KCA-H1047R | Discovery |